Dermata Therapeutics Statistics

Total Valuation

DRMA has a market cap or net worth of $4.11 million. The enterprise value is -$2.37 million.

Market Cap	4.11M
Enterprise Value	-2.37M

Important Dates

The last earnings date was Wednesday, August 13, 2025, after market close.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

DRMA has 637,811 shares outstanding. The number of shares has increased by 1,136.52% in one year.

Current Share Class	637,811
Shares Outstanding	637,811
Shares Change (YoY)	+1,136.52%
Shares Change (QoQ)	+99.14%
Owned by Insiders (%)	16.90%
Owned by Institutions (%)	2.34%
Float	415,430

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.73
P/TBV Ratio	0.73
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.47

Current Ratio	6.47
Quick Ratio	6.32
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -231.27% and return on invested capital (ROIC) is -147.48%.

Return on Equity (ROE)	-231.27%
Return on Assets (ROA)	-110.91%
Return on Invested Capital (ROIC)	-147.48%
Return on Capital Employed (ROCE)	-187.71%
Revenue Per Employee	n/a
Profits Per Employee	-$1.29M
Employee Count	8
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -71.61% in the last 52 weeks. The beta is 0.56, so DRMA's price volatility has been lower than the market average.

Beta (5Y)	0.56
52-Week Price Change	-71.61%
50-Day Moving Average	6.78
200-Day Moving Average	10.02
Relative Strength Index (RSI)	46.51
Average Volume (20 Days)	25,508

Short Selling Information

The latest short interest is 39,032, so 6.12% of the outstanding shares have been sold short.

Short Interest	39,032
Short Previous Month	100,682
Short % of Shares Out	6.12%
Short % of Float	9.40%
Short Ratio (days to cover)	0.22

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-10.54M
Pretax Income	-9.82M
Net Income	-10.33M
EBITDA	n/a
EBIT	-10.54M
Earnings Per Share (EPS)	-$20.21

Full Income Statement

Balance Sheet

The company has $6.48 million in cash and n/a in debt, giving a net cash position of $6.48 million or $10.16 per share.

Cash & Cash Equivalents	6.48M
Total Debt	n/a
Net Cash	6.48M
Net Cash Per Share	$10.16
Equity (Book Value)	5.61M
Book Value Per Share	8.80
Working Capital	5.61M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-10.96M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,136.52%
Shareholder Yield	-1,136.52%
Earnings Yield	-251.27%
FCF Yield	n/a

Analyst Forecast

The average price target for DRMA is $30.00, which is 365.48% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$30.00
Price Target Difference	365.48%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on August 1, 2025. It was a reverse split with a ratio of 1:10.

Last Split Date	Aug 1, 2025
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	1